Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Hodgkin Disease × avelumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 27 Carcinoma, Transitional Cell 22 Urinary Bladder Neoplasms 21 Neoplasms 20 Carcinoma, Merkel Cell 19 Neoplasm Metastasis 17 Colorectal Neoplasms 15 Carcinoma, Renal Cell 15 Breast Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 12 Ovarian Neoplasms 12 Triple Negative Breast Neoplasms 8 Head and Neck Neoplasms 8 Pancreatic Neoplasms 7 Stomach Neoplasms 6 Melanoma 6 Recurrence 5 Prostatic Neoplasms 5 Carcinoma, Hepatocellular 5 Ureteral Neoplasms 4 Small Cell Lung Carcinoma 4 Neuroendocrine Tumors 4 Glioblastoma 4 Carcinoma, Squamous Cell 4 Uterine Cervical Neoplasms 3 Urethral Neoplasms 3 Turcot syndrome 3 Skin Neoplasms 3 Sarcoma 3 Lymphoma 3

Interventions

Cyclophosphamide 179 fludarabine phosphate 105 Etoposide 100 Peripheral Blood Stem Cell Transplantation 90 Filgrastim 82 Mycophenolic Acid 80 Doxorubicin 78 Whole-Body Irradiation 73 Melphalan 73 Radiotherapy 68 Brentuximab Vedotin 68 Tacrolimus 66 fludarabine 63 Busulfan 63 Vinblastine 59 Cyclosporine 58 Rituximab 56 Dacarbazine 49 Gemcitabine 48 Granulocyte Colony-Stimulating Factor 47 Bleomycin 47 Vincristine 43 Antilymphocyte Serum 43 Prednisone 41 Nivolumab 40 Cytarabine 40 Methotrexate 39 Carmustine 34 pembrolizumab 31 Sirolimus 27

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03617666 2023-12-12

AVENuE

University College, London

Phase 2 Unknown

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡